[go: up one dir, main page]

WO2021031784A9 - 靶向cd3和cd20的双特异性抗体及其应用 - Google Patents

靶向cd3和cd20的双特异性抗体及其应用 Download PDF

Info

Publication number
WO2021031784A9
WO2021031784A9 PCT/CN2020/103731 CN2020103731W WO2021031784A9 WO 2021031784 A9 WO2021031784 A9 WO 2021031784A9 CN 2020103731 W CN2020103731 W CN 2020103731W WO 2021031784 A9 WO2021031784 A9 WO 2021031784A9
Authority
WO
WIPO (PCT)
Prior art keywords
bispecific antibody
antibody targeting
preparation
fab molecule
chain fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2020/103731
Other languages
English (en)
French (fr)
Other versions
WO2021031784A1 (zh
Inventor
杨洋
尹伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2022511021A priority Critical patent/JP2022545234A/ja
Priority to US17/636,440 priority patent/US20220298242A1/en
Publication of WO2021031784A1 publication Critical patent/WO2021031784A1/zh
Publication of WO2021031784A9 publication Critical patent/WO2021031784A9/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

公开了抗CD3单链Fab分子和抗CD20单链Fab分子以及它们在制备双特异性抗体中的应用。还提供了靶向CD3和CD20的双特异性抗体及其在制备用于治疗B细胞相关疾病的药物中的应用。
PCT/CN2020/103731 2019-08-19 2020-07-23 靶向cd3和cd20的双特异性抗体及其应用 Ceased WO2021031784A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022511021A JP2022545234A (ja) 2019-08-19 2020-07-23 Ｃｄ３とｃｄ２０を標的とする二重特異性抗体及びその使用
US17/636,440 US20220298242A1 (en) 2019-08-19 2020-07-23 Bispecific Antibody Targeting CD3 and CD20 and Use Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910764107.6 2019-08-19
CN201910764107.6A CN112390882A (zh) 2019-08-19 2019-08-19 靶向cd3和cd20的双特异性抗体及其应用

Publications (2)

Publication Number Publication Date
WO2021031784A1 WO2021031784A1 (zh) 2021-02-25
WO2021031784A9 true WO2021031784A9 (zh) 2021-04-22

Family

ID=74603396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/103731 Ceased WO2021031784A1 (zh) 2019-08-19 2020-07-23 靶向cd3和cd20的双特异性抗体及其应用

Country Status (4)

Country Link
US (1) US20220298242A1 (zh)
JP (1) JP2022545234A (zh)
CN (1) CN112390882A (zh)
WO (1) WO2021031784A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN116023499B (zh) * 2022-10-26 2024-01-23 北京力邦生物医药科技有限公司 一种针对cd3和cd20的双特异性抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120591A1 (es) * 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
DK2748201T3 (en) * 2011-08-23 2018-02-12 Roche Glycart Ag BISPECIFIC T-CELL ACTIVATING ANTIGIN BINDING MOLECULES
KR20150036606A (ko) * 2012-07-13 2015-04-07 자임워크스 인코포레이티드 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
CA2878587A1 (en) * 2012-07-23 2014-01-30 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR20150122761A (ko) * 2013-02-26 2015-11-02 로슈 글리카트 아게 Ｔ 세포 활성화 항원 결합 분자
US10164870B2 (en) * 2013-06-28 2018-12-25 Avago Technologies International Sales Pte. Limited Relaxed ordering network
CA2917886A1 (en) * 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding constructs
CN104829727B (zh) * 2015-01-21 2019-03-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd19×cd3的构建及应用
US9927299B2 (en) * 2015-12-15 2018-03-27 Trutag Technologies, Inc. Spectral reading using synchronized LED sources
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
EP3559034B1 (en) * 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
US11851489B2 (en) * 2017-06-01 2023-12-26 Universität Stuttgart Heterodimerizing Ig domains
CN108059680B (zh) * 2017-12-26 2020-07-24 北京东方百泰生物科技有限公司 一种针对cd20和cd3的双特异性抗体
WO2019228406A1 (en) * 2018-05-29 2019-12-05 Wuxi Biologics (Shanghai) Co., Ltd. A novel anti-cd3/anti-cd20 bispecific antibody
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用

Also Published As

Publication number Publication date
US20220298242A1 (en) 2022-09-22
JP2022545234A (ja) 2022-10-26
CN112390882A (zh) 2021-02-23
WO2021031784A1 (zh) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2021005396A (es) Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
WO2020016662A3 (en) Antibodies specific to trophoblast antigen 2 (trop2)
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
EA201990787A1 (ru) Биспецифичное антитело к всма и cd3 и иммунологическое лекарственное средство для комбинированного применения в лечении множественной миеломы
IL290512A (en) Pharmaceutical preparations containing bispecific antibodies directed against CD3 and CD20 and their uses
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MX2020007697A (es) Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
MY208638A (en) Anti-steap1 antigen-binding protein
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
SA523440623B1 (ar) أجسام مضادة
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2023002805A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos.
WO2023280092A9 (zh) 抗体药物偶联物及其应用
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
WO2018213064A8 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2021002531A (es) Anticuerpo anti-cd38, fragmento de union al antigeno y uso farmaceutico.
WO2018140845A3 (en) Bi-specific antibodies to cd64 and a disease antigen
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2019015914A (es) Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
MX2025005088A (es) Métodos para tratar cánceres
WO2021031784A9 (zh) 靶向cd3和cd20的双特异性抗体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20854161

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022511021

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20854161

Country of ref document: EP

Kind code of ref document: A1